Skip to main content

Xceleron and Servier to Accelerate Drug Development Using Microdosing

NEW YORK, Dec. 8, (GenomeWeb News) - Under a collaborative agreement, XCeleron will provide Servier accelerator mass spectrometry services to study candidate drugs in humans, Xceleron said yesterday.


Servier will accelerate drug development by testing candidate drugs in phase 0 microdose studies instead of waiting for conventional phase 1 studies.


The 12-month rolling agreement allows the pharmaceutical company to include early human studies as part of its drug candidate selection process, Xceleron said.


Financial details were not disclosed.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.